Bariatric Surgery – Commercial and Individual Exchange Medical Policyopen_in_new - OpenPayer
CurrentUnitedHealthcarePolicy 2026T0362RR
Bariatric Surgery – Commercial and Individual Exchange Medical Policyopen_in_new
UnitedHealthcare medical policy defining medically necessary and not medically necessary bariatric surgical procedures and criteria for Commercial and Individual Exchange plans (with state-specific exclusions and Maryland regulatory criteria included). This part covers covered procedures, indications by age, preoperative requirements, revisional surgery indications, unproven procedures, applicable CPT/HCPCS codes, definitions, benefit considerations, and clinical evidence excerpts.
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery – Commercial and Individual Exchange Medical Policyopen_in_new
Policy CodePolicy 2026T0362RR
Change TypeDefinitions, criteria, documentation, and unproven procedure list updated
Effective DateMay 1, 2026
Next Review Date
Key ActionSubmit documentation of detailed weight history, dietary and physical activity patterns, and a psychosocial-behavioral evaluation to support medical necessity requests.
Replaced references to NAFLD with MASLD and updated related definitions.
Revised coverage criteria for planned two-stage procedures and changed language from 'compliant' to 'adherent' regarding nutrition and exercise.
Updated documentation requirements including adding items like indication of procedure type (initial/planned two-stage/revision/removal), preoperative evaluation, physical activity patterns, recent diagnostic testing, and physician's treatment plan.
Added unproven/not medically necessary procedure: Silastic ring vertical gastric bypass.
Added unproven/not medically necessary procedure: Transoral endoscopic surgery including transoral outlet reduction (TORe).
Removed 'stomach aspiration therapy' from the unproven/not medically necessary list.
Replaced various procedure groupings to explicitly list 'transoral endoscopic surgery including...' for gastrointestinal liners, intragastric balloon, and endoscopic sleeve gastroplasty (includes OverStich™).
Added Maryland fully insured group policy criteria per COMAR (BMI thresholds, age, psychological exam, structured diet program completion definitions and documentation).
Updated supporting information sections (Description of Services, Clinical Evidence, FDA, References) to reflect current information.
4Proven/Medically Necessary Procedures Listed
≥12CPT Codes Listed
MultipleUnproven/Not Medically Necessary
low‑to‑moderateQuality of Evidence
6 moIGB duration (temporary)
notedNeed for RCTs/Long-term Data
Coverage Summary
Policy effective 05/01/2026. UnitedHealthcare Commercial and Individual Exchange medical policy defining when bariatric procedures are medically necessary and listing procedures considered unproven / not medically necessary. The policy covers adult and adolescent indications, preoperative requirements, planned two‑stage procedures, revisional surgery indications, documentation requirements, and an applicable CPT code list.
Covered (proven/medically necessary) procedures include RYGB, sleeve gastrectomy, adjustable gastric banding, and biliopancreatic diversion / duodenal switch (BPD/DS) when criteria are met. The policy specifies adult BMI thresholds (e.g., ≥ 40 kg/m2 or ≥ 35–39.9 kg/m2 with specified comorbidities) and adolescent criteria (multidisciplinary center evaluation and Class II/III thresholds). Preoperative psychosocial evaluation or participation in a multidisciplinary preparatory regimen is required.
Unproven / not medically necessary procedures are explicitly listed (examples: transoral endoscopic surgery including ESG, gastrointestinal liners, intragastric balloons, TORe, TransPyloric Shuttle, silastic ring vertical gastric bypass, VBLOC, LGCP, mini‑gastric bypass/OAGB, SADS listed among others).
Maryland‑specific COMAR requirements are added for fully insured group policies: COMAR criteria for BMI and comorbidities, age ≥ 18, psychological exam, and structured diet program completion documentation options (one program for six consecutive months or two programs for three consecutive months within the prior two years). Benefit coverage remains subject to the member specific benefit document and many benefit plans exclude bariatric surgery.
Quick-reference thresholds
Adult BMI eligibilityBMI ≥40 kg/m2 (≥37.5 kg/m2 Asian) OR BMI 35–39.9 kg/m2 (32.5–37.4 kg/m2 Asian) with ≥1 specified comorbidity
Adolescent thresholdsClass III obesity OR Class II obesity with ≥1 comorbidity; Class II = 120% of 95th percentile or BMI 35–39.9; Class III = 140% of 95th percentile or BMI ≥40
OSA severity thresholdObstructive sleep apnea confirmed by polysomnography with AHI or RDI ≥30 qualifies as a comorbidity
Planned two‑stage timingInitial BMI ≥50 kg/m2 before first stage; second stage must occur within 2 years of primary procedure; patient must be adherent to nutrition and exercise
IGB durationIntragastric balloons are temporary—maximum placement duration 6 months
Revisional nutritional risk thresholdsHigh nutritional deficiency risk when common channel (CC) <200 cm or total alimentary limb length (TALL) <400 cm after RYGB distalization; requires aggressive supplementation and monitoring
Medical‑Necessity Criteria
Adults (≥ 18 years) - Medically Necessary Bariatric Surgery
Covered when ALL of the following are met:
ALL of the following
One of the following:
Body Mass Index (BMI) of ≥ 40 kg/m2 (or BMI ≥ 37.5 kg/m2 in individuals of Asian descent)≥ 40 kg/m2
BMI of 35.0 to 39.9 kg/m2 (or BMI 32.5 to 37.4 kg/m2 in individuals of Asian descent) in the presence of one or more comorbidities35.0-39.9 kg/m2
Comorbidity examples (one or more):
Unproven / Not Medically Necessary Procedures
Unproven / Not Medically Necessary Procedures
The following procedures are unproven and not medically necessary for treating obesity due to insufficient evidence of efficacy:
Unproven / Not Medically Necessary Procedures (any)
Revisional for other indications: Revisional Bariatric Surgery for any other indication than those listed above
Non-obesity primary indications: Bariatric surgery as the primary treatment for any condition other than obesity
Bariatric artery embolization
Gastric electrical stimulation with an implantable gastric stimulator
Indications, Guideline Highlights and Evidence Summaries
Indications and Candidate Selection (Guideline-based)
Professional society recommendations summarized for candidacy for metabolic/bariatric surgery and device therapies:
Guideline-based indications (any)
ASMBS/IFSO 2023: ASMBS/International Federation (2023): MBS recommended for patients with BMI ≥ 35 kg/m2 regardless of comorbidities; should be considered for patients with metabolic disease and BMI 30–34.9 kg/m2≥35 kg/m2; consider 30–34.9
ADA 2024: ADA (2024): Consider metabolic surgery for patients with diabetes and BMI ≥ 30.0 kg/m2 (≥ 27.5 kg/m2 in Asian American patients)≥30 kg/m2 (≥27.5 Asian)
Endoscopic Bariatric Therapies and Device Evidence Statements
Summary of evidence quality and conclusions for specific devices/procedures:
Endoscopic and device evidence statements
Intragastric Balloons (IGBs): Level 1 data from RCTs exist; IGB therapy results in notable weight loss during treatment; safety profile acceptable though early intolerance and early removal common; FDA-approved IGBs are temporary (maximum 6 months) and should be used with multidisciplinary follow-up and lifestyle modificationIGB duration max 6 months
DUO trial (DBS): Dual intragastric balloon system (DUO trial): RCT (n=326) met coprimary endpoints at 24 weeks; DUO group had greater %EWL (ITT 25.1% vs DIET 11.3%) and higher responder rate; device AEs included deflation (6%), early retrieval for intolerance (9%), gastric ulcers (10% reduced after device change)
Preoperative and Perioperative Recommendations
Presurgical and Perioperative Recommendations
Guidance from societies on preoperative evaluation and perioperative care:
Psychosocial evaluation: ASMBS recommends presurgical psychosocial evaluation by behavioral health clinicians and availability of postoperative psychosocial care; no RCT evidence supports mandated preoperative weight loss as a requirement
Nutritional guidelines: ASMBS nutritional guidelines: preoperative education about expected nutrient deficiencies; preoperative screening for vitamin deficiencies important; postoperative monitoring and supplementation are the responsibility of the bariatric program
AGA on IGBs: recommend concomitant moderate- to high-intensity lifestyle modification, PPI prophylaxis during IGB therapy, perioperative antiemetics and anesthetic regimens to reduce nausea; suggest against routine perioperative lab screening for nutritional deficiencies but suggest daily adult-dose multivitamin supplementation
Revisional Surgery — Outcomes and Nutritional Risks
Revisional Surgery and Nutritional Risks
Key safety considerations for revisional procedures:
Nutritional risk thresholds: RYGB distalization as a revisional procedure results in significant weight loss but increases risk of severe macro- and micronutrient deficiencies, especially if common channel (CC) < 200 cm or total alimentary limb length (TALL) < 400 cm; requires aggressive vitamin supplementation and regular nutrition monitoringCC <200 cm; TALL <400 cm
Higher complication rates: Revisional bariatric surgery has higher complication rates versus primary procedure (examples: reported complication rates up to 41% vs 15% for primary procedures); careful patient selection and informed consent required
Reoperation types include corrective, conversion, and reversal; reoperations comprise corrective (~69.5%) and conversions (~30.5%) in reported datasets
Pediatric Eligibility Guidance
Pediatric Eligibility Guidance (from AAP and Endocrine Society)
Summarized recommendations from professional societies for considering metabolic/bariatric surgery (MBS) in children/adolescents:
AAP age and BMI thresholds: AAP: patient > 12 years with either Class II obesity and BMI ≥ 35 kg/m2 or 120% of the 95th percentile for age/sex with clinically significant disease, OR Class III obesity with BMI ≥ 40 kg/m2 or 140% of 95th percentile for age/sex, whichever is lowerClass II: ≥120% of 95th pct or BMI≥35; Class III: ≥140% or BMI≥40
Clinically significant disease examples listed in policy
Family stability and multidisciplinary team: Requires stability and competence of family unit via psychological evaluation, ability to adhere to healthy dietary/activity habits, access to experienced pediatric bariatric center
Coding
Billing Rule
Billing and provider actions
Report laparoscopic sleeve gastrectomy with CPT 43775 rather than using the unlisted code 43659. Ensure prior authorization and documentation include multidisciplinary evaluation, preoperative psychosocial and nutritional evaluation, and evidence of adolescent multidisciplinary center consultation when applicable. For revisional procedures, document indication (e.g., device migration/slippage with attempted non-surgical correction, leak, obstruction, staple-line failure), evidence supporting revisional surgery, counseling on revisional risks including nutritional deficiencies, and plan for postoperative nutritional monitoring (including for distalization procedures). Intragastric balloon (IGB) devices require documentation of device type, insertion date, planned duration of implantation, and follow-up plan; removal or revisional interventions must be supported by clinical evidence. Investigational interventions (including endoscopic sleeve gastroplasty, intragastric balloon for primary obesity treatment outside FDA indications, bariatric artery embolization, VBLOC, mini-gastric bypass, and others listed in policy) should be approached with caution and, where considered, involve research/registry participation and clear informed consent. Prior Authorization / Review Documentation: include complete medical records demonstrating meeting criteria (BMI, comorbidities), prior nonoperative management, multidisciplinary care notes, psychosocial evaluation, nutritional evaluation, operative reports, imaging/endoscopy supporting complication or device failure, and pediatric referral documentation when applicable.
Use CPT 43775 for laparoscopic sleeve gastrectomy; do not report unlisted code 43659 for this procedure.
For adolescents (12–17 years): include documentation of consultation with or evaluation at a multidisciplinary bariatric center (accredited by MBSAQIP or demonstrates equivalent programmatic components).
Provider Actions & Documentation Requirements
Prior Authorization / Documentation
Risk/Consent and Billing Rules
Documentation Required
Two-stage procedure adherence and timing
For planned two-stage procedures document: initial BMI ≥ 50 kg/m2 before the first-stage procedure; evidence the individual has been adherent to nutrition and exercise; and that the second-stage procedure occurs within 2 years of the primary bariatric surgery. Also document that the individual meets medical necessity criteria at the time of the second stage.
Initial BMI ≥ 50 kg/m2 prior to first-stage procedure
Second stage occurs within 2 years of the primary bariatric surgery
Individual has been adherent to nutrition and exercise
Individual meets medical necessity criteria at time of second-stage procedure
Definitions
Term
Definition
Asian
Origins from the Far East, Southeast Asia, or the Indian subcontinent (examples listed).
Body Mass Index
Weight in kilograms divided by square of height in meters; used as screening tool with specified classification ranges.
MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease: hepatic steatosis diagnosed by imaging or histology without other causes plus metabolic criteria (BMI, glucose, BP, triglycerides, HDL cutoffs).
Obstructive Sleep Apnea (OSA)
Sleep-related breathing disorder; severity: Mild AHI/RDI ≥5 and <15; Moderate ≥15 and ≤30; Severe >30/hour.
Multidisciplinary
Bariatric center or regimen combining several disciplines (surgeon, obesity medicine, dietician, behavioral health, exercise specialist, nursing, support groups) to create safe effective care.
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy; a hypoabsorptive revisional or primary bariatric procedure.
ESG
Endoscopic sleeve gastroplasty performed with devices such as the Apollo OverStitch endoscopic suturing system.
IGB
Intragastric balloon devices (fluid-filled, gas-filled, or ingestible) used temporarily for weight loss.
DJBL / EndoBarrier
Duodenal-jejunal bypass liner, a gastrointestinal liner placed endoscopically to induce weight loss and glycemic effects while in situ.
VBLOC
Vagus nerve blocking therapy.
Revisional Bariatric Surgery
Any operation after the first bariatric operation that qualified toward center of excellence volume requirements; subdivided into corrective operations (address complications/incomplete effect without changing initial operation) and conversions (change index operation type).
Common Channel (CC)
The distal common intestinal segment in certain bypass procedures; CC length < 200 cm associated with increased nutritional deficiency risk after distalization.
Total Alimentary Limb Length (TALL)
Sum of alimentary limb (AL) plus common channel (CC); TALL < 400 cm associated with increased deficiency risk after distalization.
Structured diet program (COMAR)
Programs such as Weight Watchers or Jenny Craig; documentation acceptable includes physician notes, other provider notes, receipts, or diet/weight loss logs.
Multidisciplinary surgical preparatory regimen
Participation in a multidisciplinary program including nutritional consult as part of preoperative preparation.
Selected Evidence & Key Findings
By‑Band‑Sleeve RCT (2025, multicenter): at 3 years RYGB had the highest proportion achieving ≥50% EWL (~68%), adjustable banding ~25%, sleeve ~41%; mean TWL at 3 years was ~−26.8% (RYGB), −14.0% (band), and −19.4% (sleeve); sleeve had lower AE rates from 30 days to 3 years compared with RYGB and band.
DUO/REDUCE RCT (dual balloon system): RCT n=326 met coprimary endpoints at 24 weeks; ITT %EWL ~25.1% (DUO) vs 11.3% (DIET) with higher responder rates and device AEs including deflation (~6%) and early retrieval (~9%).
SADI‑S randomized trial (Robert et al., multicenter 2025): at 2 years SADI‑S showed higher %EWL (~−76.0%) vs RYGB (~−68.1%; MD −6.72%; p=0.026) but had higher early surgical complications (6% vs 2%) and more GI malabsorptive symptoms (steatorrhea, diarrhea).
ESG / IFSO pooled results: IFSO systematic review (2024) pooled data from 44 articles (15,714 pts) finding mean TBWL ~17.56% at 12 months, mean EWL ~53.09% at 12 months, and SAE rate ~1.25%; recognition that evidence is largely observational and long‑term data limited.
IGB RCTs and meta‑analyses: randomized studies (including adjustable and dual balloon systems) demonstrate short‑term clinically meaningful weight loss during device placement (e.g., ORBERA pooled %EWL ~25.4% at 12 months and TWL ~11–13% at 6–12 months) but weight regain after removal is common and safety/adverse event signals (early intolerance, deflation, migration) exist.
Revisional surgery evidence quality: HTAs and systematic reviews (Hayes 2025, Axer 2023) rate the evidence as low to very low quality; observational series suggest clinically meaningful weight loss after revision but with higher complication rates and uncertain comparative benefit across revisional techniques.
Revision History
2026-05-01policy_effectiveLatest
Policy changes effective 05/01/2026: Replaced references to NAFLD with MASLD; revised planned two-stage procedure language replacing 'compliant' with 'adherent' to nutrition and exercise; updated BMI history requirement from five-year to two-year and expanded documentation requirements (including indication of procedure type, preoperative evaluation, physical activity patterns, recent diagnostic testing, and physician's treatment plan); added Maryland COMAR fully insured group policy criteria and documentation examples; updated definitions including MASLD and Multidisciplinary; updated supporting sections (Description of Services, Clinical Evidence, FDA, References).
2026-05-01list_update_addedLatest
Added unproven/not medically necessary procedures: Silastic ring vertical gastric bypass and Transoral endoscopic surgery including transoral outlet reduction (TORe).
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery – Commercial and Individual Exchange Medical Policyopen_in_new
Policy CodePolicy 2026T0362RR
Change TypeDefinitions, criteria, documentation, and unproven procedure list updated
Effective DateMay 1, 2026
Next Review Date
Key ActionSubmit documentation of detailed weight history, dietary and physical activity patterns, and a psychosocial-behavioral evaluation to support medical necessity requests.
AND additional required evaluations (both required):
Completion of a preoperative evaluation including detailed weight history, dietary and physical activity patterns
Psychosocial-behavioral evaluation by a behavioral health professional to identify risk factors or potential postoperative challenges
Alternatively, participation in a multidisciplinary surgical preparatory regimen is acceptable in lieu of the two evaluations above
Multidisciplinary team includes bariatric surgeon, obesity medicine specialist, registered dietitian, behavioral health specialist, exercise specialist and specialized nursing as appropriate.
Adolescents (12-17 years) - Medically Necessary Bariatric Surgery
Covered when ALL of the following are met:
ALL of the following
One of the following:
Class III obesity (absolute BMI ≥ 40 kg/m2 or 140% of the 95th percentile for age/sex)
Class II obesity with one or more comorbidities (examples below)
Class II defined as 120% of the 95th percentile or absolute BMI 35-39.9 kg/m2, whichever is lower
Comorbidity examples (one or more):
Insulin resistance or type 2 diabetes
Poorly controlled hypertension despite pharmacotherapy (systolic >140 mm Hg or diastolic ≥ 90 mm Hg)
Hyperlipidemia
Obstructive sleep apnea confirmed on polysomnography with AHI or RDI ≥ 30AHI/RDI ≥ 30
Evidence of MASLD
Idiopathic intracranial hypertension
Evaluation at or in consultation with a multidisciplinary center focused on surgical treatment of severe childhood obesity (may include adolescent centers accredited by MBSAQIP or equivalent)
Covered when ALL of the following are met for planned two-stage procedures:
ALL of the following
Initial BMI of ≥ 50 kg/m2 prior to first-stage bariatric procedure≥ 50 kg/m2
Second-stage procedure occurs within 2 years following the primary bariatric surgery≤ 2 years
Individual has been adherent to recommended nutrition and exercise programs
Individual meets the medical necessity criteria for bariatric surgery at the time of the second-stage procedure (see Adults or Adolescents criteria as applicable)
Revisional Bariatric Surgery - Medically Necessary Indications
Revisional bariatric surgery is covered when any of the following indications are met. Documentation of the indication and prior management (as specified) must be provided.
ANY of the following
Bowel perforation (including adjustable gastric band erosion)
Adjustable gastric band migration (slippage) that cannot be corrected with manipulation or adjustment
Records must demonstrate that manipulation or adjustment was attempted
Leak
Obstruction confirmed by imaging studies
Staple-line failure
Mechanical adjustable gastric band failure
Uncontrollable reflux related to sleeve gastrectomy - ALL of:
Maximum nonpharmacological medical management failure (e.g., positional, dietary modification, behavioral changes)
Maximum pharmacological medical management failure (e.g., at least 1 month of double-dose proton pump inhibitor, H2 blocker, and/or sucralfate)
Severe esophagitis (Los Angeles grade C or D) confirmed by endoscopy despite maximum medical management
Provide endoscopy reports, medication trials, symptom history, and prior management documentation
Removal of an adjustable gastric band and all related components when removal is performed without immediate revisional reconstruction (documented)
Additional Evidence & Guideline Considerations
The following additional evidence summaries, professional society positions, and guideline highlights are incorporated in policy determinations and limitations:
{"text":"ASMBS/Revision Task Force: Revisional bariatric surgery indications and outcomes have been evaluated by the American Society for Metabolic and Bariatric Surgery Revision Task Force; policy aligns coverage for technically necessary revisional procedures for complications or major technical failures and requires documentation of prior management and rationale for revision."},{"text":"Endoscopic Sleeve Gastroplasty (ESG): International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and MERIT evidence summaries report limited durability and less weight loss compared with surgical sleeve gastrectomy; current evidence is insufficient to establish long-term efficacy for ESG as a primary obesity treatment — therefore ESG (including OverStitch ) is considered unproven/not medically necessary for treatment of obesity."},{"text":"Single-Anastomosis Duodenal-Ileal with Sleeve (SADI-S/SADS): IFSO position notes emerging data but limited long-term outcomes and higher nutritional deficiency risk compared with standard duodenal switch; due to insufficient robust comparative evidence, SADI-S/SADS is considered unproven/not medically necessary in this policy."},{"text":"NICE guidance highlights: National Institute for Health and Care Excellence cautions selective use of novel bariatric procedures pending longer-term outcome data and emphasizes multidisciplinary assessment, standardized consent, and registry reporting; policy reflects conservative coverage aligned with NICE recommendations."},{"text":"AASM and OSA-related recommendations: American Academy of Sleep Medicine guidance is used to define OSA severity thresholds (AHI/RDI \u2265 30 for severe OSA) and to require objective polysomnography confirmation when OSA is cited as an obesity comorbidity for surgical eligibility."},{"text":"VA/DoD guideline excerpts: Department of Veterans Affairs/Department of Defense guidance emphasizes comprehensive preoperative evaluation, behavioral health assessment, and multidisciplinary care pathways; policy requires similar preoperative psychosocial and multidisciplinary evaluations prior to approval."},{"text":"Policy Changes Effective 05/01/2026: - Clarified BMI thresholds for individuals of Asian descent (BMI \u2265 37.5 kg/m2 and 32.5-37.4 kg/m2 ranges). - Explicit inclusion of MASLD as qualifying comorbidity. - Updated adolescent multidisciplinary center consultation requirement to include MBSAQIP-accredited adolescent centers or equivalent. - Added explicit documentation requirements for revisional surgery (e.g., attempted band adjustments, endoscopy reports, medication trials for reflux). - Reaffirmed classification of ESG, SADI-S/SADS, mini-gastric/one-anastomosis bypass, gastric electrical stimulation, bariatric artery embolization, intragastric devices, vagus nerve blocking, and other listed interventions as unproven/not medically necessary due to insufficient evidence."}]
IGB: Intragastric balloonmaximum 6 months when used (device-specific)
TORe: Transoral outlet reduction (TORe)
TransPyloric Shuttle device
VBLOC: Vagus nerve blocking (VBLOC®)
AACE/ASMBS 2019: AACE/ASMBS (2019): Patients with BMI ≥ 40 kg/m2 eligible; BMI ≥ 35 kg/m2 with one or more severe obesity-related complications should be considered; BMI 30–34.9 kg/m2 with T2D and inadequate glycemic control despite optimal therapy should be considered≥40; ≥35 with complications; 30–34.9 with T2D
AHA/ACC 2013: AHA/ACC/The Obesity Society (2013 update): Recommend bariatric surgery for BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with comorbidities≥40 or ≥35 with comorbidity
Bariatric surgical approaches include restrictive, malabsorptive, or combined operations. Restrictive methods reduce gastric volume; malabsorptive methods limit intestinal absorption; many procedures include both mechanisms and can be performed open or laparoscopically.
Commonly performed procedures described include Roux‑en‑Y gastric bypass (RYGB), sleeve gastrectomy (VSG/LSG), laparoscopic adjustable gastric banding (LAGB), and biliopancreatic diversion with duodenal switch (BPD/DS). Purpose and goals are to induce substantial weight loss, reduce obesity‑related comorbidities, and improve quality of life; in adolescents the goal includes reducing lifelong morbidity.
Adolescent considerations: eligibility uses BMI thresholds relative to age/percentiles (Class II/III definitions), requires multidisciplinary adolescent center evaluation (MBSAQIP‑accredited or equivalent), and emphasizes multidisciplinary follow‑up and psychosocial assessment.
Note: Benefit plans often exclude bariatric surgery; coverage is determined by the member specific benefit plan and applicable laws.
Endoscopic bariatric therapies: evidence is mixed with short‑term weight loss signals but limited long‑term durability. Network and systematic reviews indicate LSG most effective at 6–12 months; ESG shows meaningful short‑term TBWL (IFSO/pooled TBWL ~ ~17.6% at 12 months) and pooled EWL (~53% at 12 months) but evidence is largely observational; ASGE PIVI thresholds met for some EBTs (e.g., transoral outlet reduction pooled TWL 8.9% meeting the 5% PIVI threshold, pursestring pattern 12.8% TWL).
ESG: IFSO pooled review (44 articles, 15,714 pts) reports mean TBWL ~ 15.66% at 6 mo and 17.56% at 12 mo, with an SAE rate ~ 1.25%; randomized trial evidence shows ESG + lifestyle outperforms lifestyle alone but yields less weight loss than surgical LSG.
SADI‑S: randomized data (Robert et al.) show superior %EWL at 2 years vs RYGB (SADI‑S ~‑76.0% vs RYGB ~‑68.1%; MD −6.72%; p=0.026) but with higher early surgical complications and more malabsorptive symptoms (steatorrhea, diarrhea); evidence overall limited by follow‑up and nutritional deficiency concerns.
VBLOC (vagal blocking): pivotal ReCharge trial did not meet prespecified coprimary efficacy objectives despite some weight loss advantage in reports; longer‑term and additional randomized data are insufficient.
Intragastric balloons (IGBs): RCTs and meta‑analyses demonstrate notable short‑term weight loss during treatment (temporary devices, max 6 months); long‑term maintenance after explant is inconsistent and weight is often regained. Safety concerns include early intolerance, deflation/migration and need for early removal.
DJBL / EndoBarrier: systematic reviews report improved weight and glycemic parameters while device in situ (e.g., BMI reduction ~4.8 kg/m2 at 12 mo, pooled EWL ~41.3%), but early removal rates (~19%) and SAEs (~17%) including hepatic abscess limit use; NICE recommends use only in research.
DUO/DBS dual balloon RCT (REDUCE/DUO): RCT n=326 met coprimary endpoints at 24 weeks; DUO group had greater %EWL (ITT ~25.1% vs 11.3%) and higher responder rates; device AEs included deflation (~6%), early retrieval for intolerance (~9%), and gastric ulcers (reduced after device modification).
Notable RCTs/meta‑analyses summarized include By‑Band‑Sleeve (2025 RCT) showing RYGB > sleeve > band for weight loss at 3 years; Monteiro Delgado meta‑analysis (2025) demonstrating greater long‑term weight loss and T2D remission with RYGB vs sleeve but higher late complications with RYGB; numerous HTAs conclude that many endoscopic and novel devices require further RCTs and long‑term data.
TransPyloric Shuttle / transoral endoscopic gastrointestinal bypass device: evidence inconclusive per ECRI; single RCT and small case series show promising short-term weight loss but limited by small sample sizes and short follow-up; longer-term RCTs needed
VBLOC: Vagus nerve blocking (VBLOC/Maestro): ReCharge pivotal randomized sham-controlled trial did not meet prespecified coprimary efficacy objectives; other studies show some weight loss and comorbidity improvements but long-term efficacy evidence insufficient
Endoscopic sleeve gastroplasty / TORe: Endoscopic sleeve gastroplasty / transoral outlet reduction: ASGE systematic review/meta-analysis pooled TWL 8.9% at 6–12 months meeting PIVI threshold; pursestring suture pattern associated with superior outcomes (12.8% TWL)TWL ~8.9% (pooled); pursestring 12.8%
ESG (IFSO / MERIT and ECRI findings): IFSO systematic review (44 articles, 15,714 individuals) found mean EWL ~ 53.09% at 12 months and mean TBWL ~ 17.56% at 12 months, with an overall SAE rate of ~ 1.25%. Evidence is largely observational with one RCT; ESG is endorsed as effective particularly for class I/II obesity or class III patients not suitable for traditional surgery, but long‑term (>5 year) data are limited.
Intragastric balloons (IGBs): FDA‑approved devices are temporary (maximum 6 months). Trials and HTAs report clinically significant short‑term weight loss but frequent early intolerance and early removal; multidisciplinary follow‑up and lifestyle modification are recommended. Orbera and other IGBs meet ASGE PIVI thresholds in pooled analyses for short‑term TWL/EWL.
Duodenal‑jejunal bypass liner (DJBL/EndoBarrier): systematic reviews show in‑situ benefits for BMI, EWL and HbA1c at 12 months but a pooled early removal rate (~19%) and SAE rate (~17%) (migration, hemorrhage, obstruction, hepatic abscess); long‑term benefits after explantation are limited and NICE recommends use only in research.
DUO/DBS RCT details: the REDUCE pivotal DUO trial (n=326) met coprimary endpoints at 24 weeks: ITT %EWL ~ 25.1% (DUO) vs 11.3% (DIET) and higher responder rate (ITT 49.1%); device‑related AEs included balloon deflation (~6%), early retrieval for intolerance (~9%), and gastric ulcers (reduced after device modification).
Device‑specific safety/effectiveness nuances emphasized: most endoscopic/devicelike therapies show short‑term efficacy while in place but weight regain is common after removal; many devices require multidisciplinary follow‑up, PPI prophylaxis for IGBs, antiemetic strategies, and careful monitoring for device migration/deflation or GI complications; longer‑term comparative RCTs are generally lacking.
Adolescents
ASMBS pediatric guidance for adolescent MBS candidacy:
Adolescent-specific guidance
BMI thresholds for adolescents: Use BMI thresholds relative to 95th percentile: BMI ≥ 20% of 95th percentile with a comorbidity or BMI ≥ 140% of 95th percentile for surgery candidacy; Tanner stage and linear growth should not be used to determine readinessClass II: ≥120% of 95th pct; Class III: ≥140% of 95th pct or absolute BMI cutoffs
No prior weight-loss attempts required: Do not require prior weight‑loss attempts as barrier; consider earlier surgical intervention (BMI <45 kg/m2) to reduce long-term morbidity; multidisciplinary teams required and transition plan to adult MBS program necessary
Revisional surgery evidence indicates higher risk and variable effectiveness compared with primary procedures. Reoperations are classified as corrective (address complication without changing index operation) or conversion (change to a different bariatric operation); among reported reoperations ~ 69.5% corrective, 30.5% conversions.
Outcomes after revisional procedures: pooled observational data show percent EWL after revision ~ 44.5% (6 mo), 55.7% (12 mo), 59.7% (24 mo); mean EBWL after conversion ~ 39.3% and after corrective ~ 35.9% versus primary operations ~ 43.5% (ASMBS task force).
Safety comparisons: revisional surgery is associated with higher complication rates than primary procedures (examples: one study reported complications 41% vs 15% for revision vs primary). Specific comparisons show conversion to RYGB after failed LAGB had higher bleed, 30‑day readmission and reoperation rates versus conversion to LSG; some meta‑analyses indicate higher early morbidity with conversions to certain procedures.
Selection considerations: choice between conversion and corrective operations depends on index procedure, anatomy, weight/comorbidities, and surgeon experience. Evidence quality is generally low to very low; systematic reviews and HTAs conclude insufficient high‑quality data to establish superiority of specific revisional approaches and recommend individualized selection and careful counseling about elevated risks and nutritional monitoring.
Contraindications (any one):
Contraindications include: pre-adolescent children; pregnant/breastfeeding adolescents or planning pregnancy within 2 years; patient who has not mastered healthy dietary/activity habits; unresolved substance use, active eating disorder, or untreated psychiatric disorder
For adjustable gastric band migration/slippage: document attempts at manipulation/adjustment prior to revisional surgery and imaging/endoscopic confirmation of migration/slippage.
Counsel patients regarding revisional surgery risks (including higher morbidity, nutritional deficiencies, need for lifelong follow-up) and document informed consent.
Pediatric/adolescent postoperative follow-up: schedule multidisciplinary follow-up including bariatric surgeon, pediatrician/endocrinologist, dietitian, and behavioral health, with documented monitoring of growth, nutritional status, and psychosocial adjustment.
Investigational interventions: document rationale, inform patient of investigational status, and consider enrollment in research registries where available.
Preoperative psychosocial and nutritional evaluation must be completed and documented prior to approval.
Multidisciplinary care and follow-up must be documented for all candidates; include team members and follow-up plan.
For intragastric balloon devices: document device model, insertion date, planned removal date (within approved duration), and structured follow-up for monitoring and complications.
For revisional bariatric procedures and distalization: include pre- and postoperative nutritional monitoring plan (labs, supplementation plan) and long-term follow-up strategy.
Refer adolescents to a multidisciplinary pediatric bariatric center when criteria met; include referral notes in prior authorization package.
Consider research/registry participation for select or investigational procedures and document enrollment when applicable.
Prior Authorization: include complete clinical records showing BMI, comorbidities, prior conservative management, psychosocial and nutritional evaluations, multidisciplinary consultation, and operative/imaging reports supporting indications for revisional surgery.
Documentation Required
Medical Records Documentation Requirements
Provide the listed medical records items with every request: indicate the procedure requested and whether it is initial, planned two-stage, revision, or removal; preoperative evaluation (detailed weight history, dietary and physical activity patterns); current and two-year BMI history; treatments tried/failed/contraindicated with dates, duration, and reason for discontinuation; psychosocial-behavioral evaluation; participation in a multidisciplinary surgical preparatory regimen including nutritional consult; results of recent relevant diagnostic testing; physician's treatment plan; for adolescents include obesity class; for revisions include date of initial surgery, details of complications, and complete staged surgical plan.
Procedure requested and whether initial, planned two-stage, revision, or removal
Preoperative evaluation including detailed weight history, dietary and physical activity patterns
Current and two-year BMI history
Treatments tried, failed, or contraindicated with dates, duration, and reason for discontinuation
Psychosocial-behavioral evaluation
Participation in a multidisciplinary surgical preparatory regimen, including nutritional consult
Results of recent relevant diagnostic testing and physician's treatment plan
For adolescents: include obesity class
For revisions: date of initial surgery, details of complications, and complete (staged) surgical plan
Key evidence metrics
DUO (dual balloon) trial %EWL at 24 weeksDUO mean %EWL (ITT) 25.1% vs diet 11.3% at 24 weeks
ESG pooled TBWL at 12 monthsESG mean TBWL at 12 months 17.56% (IFSO pooled)
SADI‑S vs RYGB %EWL at 2 yearsSADI‑S %EWL −76.0% vs RYGB −68.1% (MD −6.72%; p=0.026) at 2 years
ESG serious AE rateIFSO pooled serious adverse event rate for ESG 1.25% (15,928 procedures)
ESG RCT (MERIT) primary 52‑week findingsRandomized trial showed ESG + lifestyle > lifestyle alone for weight loss at 52 weeks (Abu Dayyeh MERIT)
DUO responder rateDUO responder rate (ITT) 49.1% at 24 weeks (≥25% EWL)
2026-05-01list_update_removedLatest
Removed 'stomach aspiration therapy' from the unproven/not medically necessary list.
2026-05-01list_update_revisedLatest
Consolidated and clarified transoral endoscopic surgery grouping to explicitly list 'transoral endoscopic surgery including gastrointestinal liners, intragastric balloon, and endoscopic sleeve gastroplasty (includes OverStich™)'.
2026-05-01documentation_changeLatest
Updated medical records documentation requirements: indicate procedure requested and whether initial/planned two-stage/revision/removal; include preoperative evaluation, physical activity patterns, recent relevant diagnostic testing, physician's treatment plan; current and two-year BMI history; treatments tried/failed/contraindicated with dates/duration/reason; psychosocial-behavioral evaluation; participation in multidisciplinary surgical preparatory regimen including nutritional consult; for adolescents include obesity class; for subsequent surgery include date of initial surgery, complication details, and complete staged surgical plan.